procarbazine has been researched along with Glial Cell Tumors in 129 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV)." | 9.22 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. ( Ater, JL; Booth, TN; Freyer, DR; Mazewski, CM; Packer, RJ; Pollack, IF; Sposto, R; Vezina, G; Xia, C, 2016) |
| "A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG)." | 9.16 | Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Coons, SW; Gilbert, MR; Mehta, MP; Shaw, EG; Stelzer, KJ; Wang, M, 2012) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 9.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 9.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aims of this phase I study in patients with recurrent malignant gliomas were to determine the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating lymphocytes during treatment." | 9.09 | Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. ( Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A, 2001) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 9.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 9.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas." | 9.08 | A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). ( Adams, G; Flynn, P; Grunnet, M; Hellman, R; Karp, D; Neuberg, DS; Robins, HI; Wagner, H, 1998) |
| "Twenty patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of procarbazine, thiotepa and vincristine (P." | 9.07 | Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. ( Ameri, A; Chen, QM; Delattre, JY; Poisson, M, 1993) |
| "We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma." | 9.06 | Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. ( Baptista, J; Clark, K; Coyle, T; Graziano, S; King, R; Kirshner, J; Newman-Palmer, N; Poiesz, B; Scalzo, A; Winfield, J, 1990) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 9.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 8.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 8.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 8.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 7.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 7.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "We have studied the effects of medroxyprogesterone acetate (MPA) on C6 glioma growth in vitro in order to prove the hypothesis that it could arrest growth and induce drug sensitisation in a glial tumour as it does in breast cancer cells." | 7.71 | Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. ( Altinoz, MA; Bilir, A; Onar, FD; Ozar, E; Sav, A, 2001) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 7.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 7.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 6.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV)." | 5.22 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. ( Ater, JL; Booth, TN; Freyer, DR; Mazewski, CM; Packer, RJ; Pollack, IF; Sposto, R; Vezina, G; Xia, C, 2016) |
| "The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs)." | 5.19 | Patients with primary brain tumors. ( Behrend, SW, 2014) |
| "The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS)." | 5.19 | Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Gilbert, MR; Hu, C; Mehta, MP; Prabhu, RS; Shaw, EG; Stelzer, KJ; Won, M, 2014) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 5.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG)." | 5.16 | Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Coons, SW; Gilbert, MR; Mehta, MP; Shaw, EG; Stelzer, KJ; Wang, M, 2012) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 5.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "Procarbazine hydrochloride (PCB) is one of the few anticancer drugs with activity against high-grade gliomas." | 5.12 | The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. ( Alavi, JB; Batchelor, TT; Carson, KA; Fisher, JD; Grossman, SA; Hammour, T; Lesser, G; Mikkelsen, T; Phuphanich, S; Supko, JG, 2006) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "The aims of this phase I study in patients with recurrent malignant gliomas were to determine the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating lymphocytes during treatment." | 5.09 | Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. ( Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A, 2001) |
| " Between May 1992 and January 1998, eight children with unresectable or recurrent intramedullary glioma were treated with the BB SFOP protocol (a 16-month chemotherapy regimen with carboplatin, procarbazine, vincristine, cyclophosphamide, etoposide and cisplatin)." | 5.09 | Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). ( Chastagner, P; Chouffai, Z; Couanet, D; Doireau, V; Grignon, Y; Grill, J; Kalifa, C; Lellouch-Tubiana, A; Marchal, JC; Zerah, M, 1999) |
| "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas." | 5.08 | A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). ( Adams, G; Flynn, P; Grunnet, M; Hellman, R; Karp, D; Neuberg, DS; Robins, HI; Wagner, H, 1998) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 5.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 5.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "Twenty patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of procarbazine, thiotepa and vincristine (P." | 5.07 | Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. ( Ameri, A; Chen, QM; Delattre, JY; Poisson, M, 1993) |
| "Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of three chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin)." | 5.06 | Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA; VanGilder, JC, 1989) |
| "We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma." | 5.06 | Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. ( Baptista, J; Clark, K; Coyle, T; Graziano, S; King, R; Kirshner, J; Newman-Palmer, N; Poiesz, B; Scalzo, A; Winfield, J, 1990) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "A controlled study of 226 age-matched patients with histologically proven grade 3 and 4 supratentorial gliomas with maximum feasible tumour resection, postoperative Karnofsky performance over 50 and minimum survival of 8 weeks compares the results of supportive care (45 cases), high-dose irradiation of 40 to 66 Gy (59 cases), COMP protocol (CCNU, procarbazine, vincristine, methotrexate, prednisone in 15 day cycles-42 cases) and simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)." | 5.05 | [Combined treatment of malignant gliomas]. ( Flament, H; Grisold, W; Jellinger, K; Volc, D; Vollmer, R; Weiss, R, 1983) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 5.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy." | 4.90 | Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. ( van den Bent, MJ, 2014) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 4.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma." | 4.80 | Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 4.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 4.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 3.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| " However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival." | 3.88 | Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( Narita, Y, 2018) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 3.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "We previously developed a mathematical model capturing tumor size dynamics of adult low-grade gliomas (LGGs) before and after treatment either with PCV (Procarbazine, CCNU, and Vincristine) chemotherapy alone or with radiotherapy (RT) alone." | 3.81 | Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. ( Ducray, F; Honnorat, J; Mazzocco, P; Ribba, B, 2015) |
| "We have studied the effects of medroxyprogesterone acetate (MPA) on C6 glioma growth in vitro in order to prove the hypothesis that it could arrest growth and induce drug sensitisation in a glial tumour as it does in breast cancer cells." | 3.71 | Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. ( Altinoz, MA; Bilir, A; Onar, FD; Ozar, E; Sav, A, 2001) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 3.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 3.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "We used human anaplastic glioma xenografts to evaluate the therapeutic efficacy of combinations of alkylating drugs, either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-(2,5-dioxo-3-piperidyl)-1-nitrosourea (PCNU), or procarbazine, and thiopurines, either 6-mercaptopurine (6MP) or 6-thioguanine (6TG)." | 3.68 | Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. ( Bigner, DD; Bodell, WJ; Elion, GB; Friedman, HS; Schold, SC; Wang, AM, 1991) |
| "Twenty-six patients with intracerebral tumors (predominantly gliomas) were treated with intraarterial BCNU, VM-26, and cisplatin combined with the systemic administration of VM-26, methotrexate, vincristine, bleomycin, and procarbazine." | 3.67 | Combined intraarterial and systemic chemotherapy for intracerebral tumors. ( Benoit, B; Grahovac, Z; Hugenholtz, H; Richard, M; Russell, N; Stewart, DJ, 1987) |
| "One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation." | 3.67 | Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. ( Bozek, T; Capra, LG; Collins, CD; Darling, JL; Godlee, JN; Mooney, C; Mott, TJ; Paul, EA; Thomas, DG; Tobias, JS, 1985) |
| "Intracerebral murine glioma 26 was used as a model system for evaluating two-drug combinations of antitumor agents, BCNU was combined with either procarbazine, dianhydrogalactitol, or ellipticine." | 3.66 | Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. ( Levin, VA; Wilson, CB, 1978) |
| "A human medulloblastoma (BN-2) and a glioblastoma (BN-3) which were previously established in nude mice were used to determine the effect of combined modality therapy with gamma-radiation, and three chemotherapeutic agents, procarbazine, 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo diethylester (AZQ), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.66 | Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. ( Feola, J; Houchens, DP; Ovejera, AA; Slagel, DE, 1982) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 2.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | 2.67 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| " On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow." | 2.64 | [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. ( Buge, A; Poisson, M; Pouillart, P, 1978) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols." | 2.38 | Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. ( Levin, VA; Prados, M; Rodriguez, LA; Silver, P, 1989) |
| "Of the 13 children with a residual tumour, chemotherapy induced 2 partial responses (PR), 1 minor response (MR) and 1 stable disease (SD) with no recurrent disease." | 1.33 | High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. ( Chastagner, P; Doz, F; Dufour, C; Frappaz, D; Gentet, JC; Grill, J; Kalifa, C; Lellouch-Tubiana, A; Pichon, F; Plantaz, D; Puget, S; Raquin, MA, 2006) |
| "Procarbazine is a cytotoxic chemotherapeutic agent used in the treatment of lymphomas and brain tumors." | 1.32 | Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. ( Batchelor, TT; Grossman, S; He, X; Supko, JG, 2004) |
| " Toxic effects resulted when procarbazine, a drug of this class, was used in treating a child with a CNS tumor." | 1.28 | Monoamine oxidase inhibitor toxicity. ( Pack, R; Pfefferbaum, B; van Eys, J, 1989) |
| "Secondary acute leukemias are rare in the evolution of malignant gliomas and the usefulness of subsequent radiochemotherapy cannot be questioned at the present time." | 1.27 | Two cases of acute leukemia following treatment of malignant glioma. ( Audebert, AA; Canuel, C; Debray, J; Genot, JY; Krulik, M; Poisson, M; Renoux, M; Smadja, N; van Efferterre, R, 1983) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| " BCNU in combination with Vincristine and Procarbazine every 6 weeks." | 1.27 | Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors. ( Balsys, R; Bremer, AM; Duarte, P; Gonzalez, N; Kleriga, E; Miller, RI; Nguyen, TQ; Northup, HM, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (34.11) | 18.7374 |
| 1990's | 28 (21.71) | 18.2507 |
| 2000's | 25 (19.38) | 29.6817 |
| 2010's | 26 (20.16) | 24.3611 |
| 2020's | 6 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 1 |
| Shih, HA | 1 |
| Van der Valk, H | 1 |
| Dijkstra, H | 2 |
| Walenkamp, A | 1 |
| Schuttelaar, MLA | 1 |
| Oude Elberink, HNG | 2 |
| Van de Ven, AAJM | 2 |
| Raswoli, M | 1 |
| Nobre, L | 1 |
| Hawkins, C | 2 |
| Bartels, UK | 1 |
| Tabori, U | 2 |
| Bouffet, E | 3 |
| Cai, Y | 1 |
| Jiang, YG | 1 |
| Wang, M | 2 |
| Jiang, ZH | 1 |
| Tan, ZG | 1 |
| Keogh, RJ | 1 |
| Aslam, R | 1 |
| Hennessy, MA | 1 |
| Coyne, Z | 1 |
| Hennessy, BT | 1 |
| Breathnach, OS | 1 |
| Grogan, L | 1 |
| Morris, PG | 1 |
| Hutten, EM | 1 |
| Lambeck, AJA | 1 |
| Nuver, J | 1 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 1 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Narita, Y | 1 |
| Wick, W | 2 |
| Winkler, F | 1 |
| Prabhu, RS | 1 |
| Won, M | 1 |
| Shaw, EG | 3 |
| Hu, C | 1 |
| Brachman, DG | 2 |
| Buckner, JC | 3 |
| Stelzer, KJ | 2 |
| Barger, GR | 2 |
| Brown, PD | 2 |
| Gilbert, MR | 2 |
| Mehta, MP | 2 |
| Behrend, SW | 1 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| van den Bent, MJ | 3 |
| Schiff, D | 1 |
| Levin, VA | 17 |
| Rinne, ML | 1 |
| Wen, PY | 1 |
| Brandes, AA | 1 |
| Bartolotti, M | 1 |
| Tosoni, A | 1 |
| Franceschi, E | 1 |
| Mazzocco, P | 2 |
| Honnorat, J | 3 |
| Ducray, F | 5 |
| Ribba, B | 1 |
| Ater, JL | 2 |
| Xia, C | 1 |
| Mazewski, CM | 2 |
| Booth, TN | 2 |
| Freyer, DR | 2 |
| Packer, RJ | 2 |
| Sposto, R | 2 |
| Vezina, G | 2 |
| Pollack, IF | 2 |
| Ollier, E | 1 |
| Ricard, D | 2 |
| Kaloshi, G | 1 |
| Idbaih, A | 2 |
| Alentorn, A | 1 |
| Psimaras, D | 1 |
| Delattre, JY | 2 |
| Grenier, E | 1 |
| Samson, A | 1 |
| Goerne, R | 1 |
| Bogdahn, U | 1 |
| Hau, P | 1 |
| Huang, F | 1 |
| Kavan, P | 1 |
| Guiot, MC | 1 |
| Markovic, Y | 1 |
| Roberge, D | 1 |
| Ashley, DM | 1 |
| Riffkin, CD | 1 |
| Lovric, MM | 1 |
| Mikeska, T | 1 |
| Dobrovic, A | 1 |
| Maxwell, JA | 1 |
| Friedman, HS | 5 |
| Drummond, KJ | 1 |
| Kaye, AH | 1 |
| Gan, HK | 1 |
| Johns, TG | 1 |
| Hawkins, CJ | 1 |
| Baumert, BG | 1 |
| Stupp, R | 1 |
| DeAngelis, LM | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Felsberg, J | 1 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 1 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 1 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 1 |
| Reifenberger, G | 1 |
| von Deimling, A | 1 |
| Weller, M | 1 |
| Mishra, KK | 1 |
| Squire, S | 1 |
| Lamborn, K | 3 |
| Banerjee, A | 1 |
| Gupta, N | 1 |
| Wara, WM | 5 |
| Prados, MD | 6 |
| Berger, MS | 1 |
| Haas-Kogan, DA | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Peyre, M | 1 |
| Cartalat-Carel, S | 1 |
| Meyronet, D | 1 |
| Jouvet, A | 3 |
| Pallud, J | 1 |
| Mokhtari, K | 1 |
| Guyotat, J | 2 |
| Jouanneau, E | 2 |
| Sunyach, MP | 2 |
| Frappaz, D | 3 |
| Brada, M | 1 |
| Stenning, S | 1 |
| Gabe, R | 1 |
| Thompson, LC | 1 |
| Levy, D | 1 |
| Rampling, R | 1 |
| Erridge, S | 1 |
| Saran, F | 1 |
| Gattamaneni, R | 1 |
| Hopkins, K | 1 |
| Beall, S | 1 |
| Collins, VP | 1 |
| Lee, SM | 1 |
| Scheinemann, K | 1 |
| Bartels, U | 1 |
| Tsangaris, E | 1 |
| Huang, A | 1 |
| Dirks, P | 1 |
| Fried, I | 1 |
| Ruiz, J | 1 |
| Case, D | 1 |
| Enevold, G | 1 |
| Rosdhal, R | 1 |
| Tatter, SB | 1 |
| Ellis, TL | 1 |
| McQuellon, RP | 1 |
| McMullen, KP | 1 |
| Stieber, VW | 1 |
| Lesser, GJ | 1 |
| Zhou, T | 1 |
| Holmes, E | 2 |
| Lazarus, KH | 1 |
| Prados, M | 2 |
| Wisoff, JH | 1 |
| Coons, SW | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Erdem-Eraslan, L | 1 |
| Gravendeel, LA | 1 |
| de Rooi, J | 1 |
| Eilers, PH | 1 |
| Spliet, WG | 1 |
| den Dunnen, WF | 1 |
| Teepen, JL | 1 |
| Wesseling, P | 1 |
| Sillevis Smitt, PA | 2 |
| Kros, JM | 1 |
| Gorlia, T | 1 |
| French, PJ | 1 |
| Baker, MJ | 1 |
| Brem, S | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Phuphanich, S | 2 |
| Vos, MJ | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 2 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 2 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Ginestet, G | 1 |
| Sindou, M | 2 |
| Bret, P | 2 |
| Carrie, C | 1 |
| Ogawa, K | 2 |
| Yoshii, Y | 2 |
| Inoue, O | 2 |
| Toita, T | 2 |
| Saito, A | 2 |
| Kakinohana, Y | 2 |
| Adachi, G | 2 |
| Ishikawa, Y | 1 |
| Kin, S | 1 |
| Murayama, S | 2 |
| Newlands, ES | 1 |
| Foster, T | 1 |
| Zaknoen, S | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| He, X | 1 |
| Batchelor, TT | 2 |
| Grossman, S | 1 |
| Supko, JG | 2 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Neyns, B | 1 |
| Sadones, J | 1 |
| Chaskis, C | 1 |
| De Ridder, M | 1 |
| Keyaerts, M | 1 |
| Veld, PI | 1 |
| Michotte, A | 1 |
| Chintagumpala, MM | 1 |
| Stewart, CF | 1 |
| Kepner, J | 1 |
| McLendon, RE | 1 |
| Modrich, PL | 1 |
| McCluggage, C | 1 |
| Burger, P | 1 |
| Thompson, S | 1 |
| Rutka, J | 1 |
| Michalski, J | 1 |
| Woo, S | 1 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Horowitz, ME | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Lesser, G | 1 |
| Mikkelsen, T | 1 |
| Alavi, JB | 1 |
| Hammour, T | 1 |
| Fisher, JD | 1 |
| Iraha, S | 1 |
| Tamaki, W | 1 |
| Sugimoto, K | 1 |
| Hyodo, A | 1 |
| Dufour, C | 1 |
| Grill, J | 2 |
| Lellouch-Tubiana, A | 2 |
| Puget, S | 1 |
| Chastagner, P | 3 |
| Doz, F | 1 |
| Pichon, F | 1 |
| Plantaz, D | 1 |
| Gentet, JC | 1 |
| Raquin, MA | 1 |
| Kalifa, C | 2 |
| Yang, SH | 1 |
| Hong, YK | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kim, MC | 1 |
| Park, CK | 1 |
| Neuwelt, EA | 1 |
| Hill, SA | 1 |
| Frenkel, EP | 1 |
| Schold, SC | 5 |
| Bigner, DD | 4 |
| West, CR | 1 |
| Avellanosa, AM | 1 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Green, SB | 2 |
| Byar, DP | 1 |
| Walker, MD | 1 |
| Pistenmaa, DA | 1 |
| Alexander, E | 1 |
| Batzdorf, U | 1 |
| Brooks, WH | 1 |
| Hunt, WE | 1 |
| Mealey, J | 2 |
| Odom, GL | 1 |
| Paoletti, P | 1 |
| Ransohoff, J | 2 |
| Robertson, JT | 2 |
| Selker, RG | 2 |
| Shapiro, WR | 6 |
| Smith, KR | 1 |
| Wilson, CB | 11 |
| Strike, TA | 2 |
| Bremer, AM | 1 |
| Kleriga, E | 1 |
| Nguyen, TQ | 1 |
| Balsys, R | 1 |
| Northup, HM | 1 |
| Gonzalez, N | 1 |
| Duarte, P | 1 |
| Miller, RI | 1 |
| Jellinger, K | 2 |
| Volc, D | 2 |
| Grisold, W | 2 |
| Flament, H | 2 |
| Vollmer, R | 2 |
| Weiss, R | 2 |
| Rawlings, CE | 1 |
| Bigner, SH | 1 |
| Genot, JY | 1 |
| Krulik, M | 1 |
| Poisson, M | 4 |
| van Efferterre, R | 1 |
| Renoux, M | 1 |
| Audebert, AA | 1 |
| Canuel, C | 1 |
| Smadja, N | 1 |
| Debray, J | 1 |
| Vestnys, PS | 1 |
| Slagel, DE | 1 |
| Feola, J | 1 |
| Houchens, DP | 1 |
| Ovejera, AA | 1 |
| Podreka, I | 1 |
| Yung, WA | 1 |
| Basler, GA | 1 |
| Shapiro, JR | 2 |
| Jeremic, B | 2 |
| Grujicic, D | 1 |
| Antunovic, V | 1 |
| Djuric, L | 1 |
| Stojanovic, M | 1 |
| Shibamoto, Y | 1 |
| Cairncross, JG | 3 |
| Ameri, A | 1 |
| Chen, QM | 1 |
| Watne, K | 1 |
| Hannisdal, E | 1 |
| Nome, O | 1 |
| Hager, B | 1 |
| Hirschberg, H | 1 |
| Newton, HB | 1 |
| Bromberg, J | 1 |
| Junck, L | 1 |
| Page, MA | 1 |
| Greenberg, HS | 1 |
| Forsyth, PA | 1 |
| Haselsberger, K | 1 |
| Peterson, DC | 1 |
| Thomas, DG | 3 |
| Darling, JL | 4 |
| Kyritsis, AP | 2 |
| Yung, WK | 2 |
| Jaeckle, KA | 2 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Edwards, MS | 1 |
| Rabbitt, J | 2 |
| Davis, RL | 3 |
| Mornex, F | 1 |
| Thiesse, P | 1 |
| Mertens, P | 1 |
| Helfre, S | 1 |
| Hellman, R | 1 |
| Neuberg, DS | 1 |
| Wagner, H | 1 |
| Grunnet, M | 1 |
| Robins, HI | 1 |
| Karp, D | 1 |
| Flynn, P | 1 |
| Adams, G | 1 |
| van Groeningen, CJ | 1 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Galanis, E | 1 |
| Burch, PA | 1 |
| Schaefer, PL | 1 |
| Dinapoli, RP | 1 |
| Novotny, PJ | 1 |
| Scheithauer, BW | 1 |
| Rowland, KM | 1 |
| Vukov, AM | 1 |
| Mailliard, JA | 1 |
| Morton, RF | 1 |
| Jakacki, RI | 2 |
| Jamison, C | 2 |
| Mathews, VP | 1 |
| Heilman, DK | 1 |
| Dropcho, E | 1 |
| Cornetta, K | 1 |
| Macdonald, DR | 1 |
| Williams, DA | 1 |
| Perry, JR | 1 |
| Brown, MT | 1 |
| Gockerman, JP | 1 |
| Doireau, V | 1 |
| Zerah, M | 1 |
| Couanet, D | 1 |
| Marchal, JC | 1 |
| Grignon, Y | 1 |
| Chouffai, Z | 1 |
| Siffert, J | 1 |
| Velasquez, L | 1 |
| Allen, JC | 1 |
| Bauman, GS | 1 |
| Wara, W | 1 |
| Davis, R | 1 |
| Edwards, M | 1 |
| Malec, M | 1 |
| Boiardi, A | 1 |
| Silvani, A | 1 |
| Ciusani, E | 1 |
| Watson, A | 1 |
| Margison, G | 1 |
| Berger, E | 1 |
| Lucas, C | 1 |
| Giroux, B | 1 |
| Hess, KR | 1 |
| Wong, ET | 1 |
| Altinoz, MA | 1 |
| Bilir, A | 1 |
| Ozar, E | 1 |
| Onar, FD | 1 |
| Sav, A | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Crafts, DC | 1 |
| Schultz, MJ | 1 |
| Boldrey, EB | 4 |
| Enot, KJ | 3 |
| Pischer, TL | 2 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Gutin, P | 1 |
| Drafts, D | 1 |
| Ertel, IJ | 1 |
| Boesel, C | 1 |
| Heiss, WD | 1 |
| Turnheim, M | 1 |
| Mamoli, B | 1 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Buge, A | 2 |
| Pouillart, P | 2 |
| Palangie, T | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Young, DF | 1 |
| Jovanovic, D | 1 |
| Djuric, LJ | 1 |
| Jevremovic, S | 1 |
| Mijatovic, LJ | 1 |
| Sneed, PK | 2 |
| Gutin, PH | 4 |
| Phillips, TL | 2 |
| Weaver, KA | 2 |
| Larson, DA | 2 |
| Gumerlock, MK | 1 |
| Belshe, BD | 1 |
| Madsen, R | 1 |
| Watts, C | 1 |
| Coyle, T | 2 |
| Bushunow, P | 1 |
| Winfield, J | 2 |
| Wright, J | 1 |
| Graziano, S | 2 |
| Leibel, SA | 1 |
| Silver, P | 3 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 1 |
| Gattamaneni, HR | 1 |
| Wang, AM | 1 |
| Elion, GB | 1 |
| Bodell, WJ | 1 |
| Hannigan, J | 1 |
| Baptista, J | 1 |
| Clark, K | 1 |
| Poiesz, B | 1 |
| Kirshner, J | 1 |
| Scalzo, A | 1 |
| Newman-Palmer, N | 1 |
| King, R | 1 |
| Bradford, R | 1 |
| Sier, N | 1 |
| Stewart, DJ | 1 |
| Grahovac, Z | 1 |
| Hugenholtz, H | 1 |
| Russell, N | 1 |
| Richard, M | 1 |
| Benoit, B | 1 |
| Rodriguez, LA | 1 |
| Burger, PC | 1 |
| Mahaley, MS | 2 |
| VanGilder, JC | 1 |
| Djang, WT | 1 |
| Kurtzberg, J | 1 |
| Longee, DC | 1 |
| Halperin, EC | 1 |
| Falletta, JM | 1 |
| Coleman, RE | 1 |
| Oakes, WJ | 1 |
| Pfefferbaum, B | 1 |
| Pack, R | 1 |
| van Eys, J | 3 |
| Brent, TP | 1 |
| von Hofe, E | 1 |
| Mitra, S | 1 |
| Swenberg, JA | 1 |
| Kleihues, P | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vestnys, P | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Takaue, Y | 1 |
| Sullivan, MP | 1 |
| Ramirez, I | 1 |
| Cleary, KR | 1 |
| Albers, GW | 1 |
| Hoyt, WF | 1 |
| Forno, LS | 1 |
| Shratter, LA | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| Baram, TZ | 1 |
| Cangir, A | 1 |
| Bruner, JM | 1 |
| Martinez-Prieto, J | 1 |
| Whaley, RA | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 1 |
| Cush, S | 1 |
| Afra, D | 1 |
| Kocsis, B | 1 |
| Kerpel-Fronius, S | 1 |
| Eckhardt, S | 1 |
| Paul, EA | 1 |
| Mott, TJ | 1 |
| Godlee, JN | 1 |
| Tobias, JS | 1 |
| Capra, LG | 1 |
| Collins, CD | 1 |
| Mooney, C | 1 |
| Bozek, T | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Vasantha Kumar, AR | 1 |
| Renaudin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375] | Phase 2/Phase 3 | 370 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)[NCT05555550] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV[NCT00052455] | Phase 3 | 500 participants (Anticipated) | Interventional | 2002-10-31 | Completed | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx[NCT03843671] | Phase 2 | 400 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas[NCT00004004] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-07-31 | Completed | ||
| A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme[NCT00088400] | Phase 3 | 30 participants | Interventional | 2004-07-31 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for procarbazine and Glial Cell Tumors
| Article | Year |
|---|---|
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase III as T | 2014 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
Procarbazine--a traditional drug in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cli | 2008 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad | 1994 |
Chemotherapy for malignant gliomas.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, D | 1996 |
Acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome | 1998 |
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Hypersensit | 1992 |
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Female; Glioblastoma; Glioma; Hum | 1989 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
41 trials available for procarbazine and Glial Cell Tumors
| Article | Year |
|---|---|
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Patients with primary brain tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2014 |
Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschoo | 2016 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Di | 2011 |
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; G | 2012 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2012 |
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2013 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Alkyl and Aryl Transferases; Antineoplastic | 2006 |
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Antineoplastic Agents; Cohort Studies; Disease P | 2006 |
Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2006 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
[Combined treatment of malignant gliomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Drug Therapy, Com | 1983 |
Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Glioma; Humans; Male; Middle Ag | 1993 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Comb | 1998 |
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Glioma; | 1998 |
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1998 |
Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carboplatin; Chemotherapy, Adjuvant; Ch | 1999 |
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2000 |
Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Lymphocytes; Male; Midd | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
Topics: Adult; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Follow-Up | 1978 |
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1992 |
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; G | 1990 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
67 other studies available for procarbazine and Glial Cell Tumors
| Article | Year |
|---|---|
Successful oral desensitization and reintroduction in selected glioma patients with procarbazine-mediated hypersensitivity.
Topics: Desensitization, Immunologic; Drug Hypersensitivity; Glioma; Humans; Procarbazine | 2020 |
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Glioma; Humans; L | 2021 |
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; | 2020 |
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an | 2021 |
Successful rapid desensitization in a glioma patient with procarbazine-mediated anaphylaxis.
Topics: Anaphylaxis; Basophils; Desensitization, Immunologic; Glioma; Humans; Procarbazine | 2021 |
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Protocols; Clinical | 2015 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioma; Humans; Lomustine; | 2010 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Glio | 2003 |
Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials, Phase | 2004 |
High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child, Preschool; Cisp | 2006 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; B | 1984 |
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Topics: Animals; Carmustine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Humans; Mice; Mice, | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Two cases of acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Astrocytoma; Brain Neoplasms; Female; Glioma; Humans; Leukemia; Nitrosourea Co | 1983 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
[Results of combined modality treatment of malignant gliomas. Comparison of postoperative irradiation, chemotherapy, and combined radio-polychemotherapy (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Huma | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma.
Topics: Antineoplastic Agents; Coloring Agents; Drug Screening Assays, Antitumor; Glioma; Humans; Lomustine; | 1996 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Res | 1999 |
Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Death; | 2001 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth | 1978 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Topics: Animals; Carmustine; Dianhydrogalactitol; Drug Therapy, Combination; Ellipticines; Glioma; Lomustine | 1978 |
Treatment of adult malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Com | 1978 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
Topics: Brain Neoplasms; Drug Evaluation; Drug Therapy, Combination; Glioma; Humans; Lomustine; Nitrosourea | 1976 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphami | 1992 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA; Glioma; | 1991 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S | 1989 |
Monoamine oxidase inhibitor toxicity.
Topics: Brain Neoplasms; Child; Female; Glioma; Humans; Procarbazine; Substance-Related Disorders | 1989 |
O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.
Topics: Animals; Brain Neoplasms; Drug Resistance; Glioma; Humans; Medulloblastoma; Methyltransferases; Mice | 1989 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Second malignant neoplasm in treated Hodgkin's disease. Report of a patient and scope of the problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; G | 1986 |
Treatment response in malignant optic glioma of adulthood.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cranial Nerve Neoplasms; F | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
Salvage chemotherapy for recurrent primary brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi | 1988 |
Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1986 |
Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Female; Gli | 1985 |
Chemosensitivity testing in the treatment of malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; Lomustine; Procarba | 1985 |
Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study.
Topics: Adolescent; Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Electroencephalography; Epe | 1974 |